The current financial score of Bio Rad Laboratories Inc is 7.98. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 651.00M, representing a year-over-year decrease of 0.09%, while its net profit experienced a year-over-year decrease of 16.87%.
The current valuation score of Bio Rad Laboratories Inc is 8.72. Its current P/E ratio is 62.95, which is 2.84% below the recent high of 64.74 and 210.95% above the recent low of -69.84.
The current earnings forecast score of Bio Rad Laboratories Inc is 6.33. The average price target is 341.25, with a high of 390.00 and a low of 315.00.
The current price momentum score of Bio Rad Laboratories Inc is 2.62. Currently, the stock price is trading between the resistance level at 395.31 and the support level at 364.74, making it suitable for range-bound swing trading.
The current institutional shareholding score of Bio Rad Laboratories Inc is 7.00. The latest institutional shareholding proportion is 84.86%, representing a quarter-over-quarter decrease of 16.47%. The largest institutional shareholder is John Rogers, holding a total of 816.75K shares, representing 2.39% of shares outstanding, with 4.45% decrease in holdings.
The current risk assessment score of Bio Rad Laboratories Inc is 7.61. The company's beta value is 1.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.